Printed on 7/20/2026
For informational purposes only. This is not medical advice.
The Bristol Stool Scale is a standardized 7-type visual stool form classification commonly used in gastroenterology and primary care. It helps describe bowel habit patterns consistently over time and supports communication between patients and clinicians.
Formula: Ordinal stool-form classification from Type 1 (hard) to Type 7 (watery).
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
Patient identifies their stool type from 7 standardized categories: Type 1 (separate hard lumps like nuts), Type 2 (sausage-shaped but lumpy), Type 3 (sausage with surface cracks), Type 4 (smooth soft sausage), Type 5 (soft blobs with clear-cut edges), Type 6 (fluffy pieces with ragged edges), Type 7 (watery, no solid pieces).
Types 3–4 = normal transit (approximately 40 hours). Types 1–2 = slow transit/constipation (approximately 100 hours). Types 5–7 = fast transit/diarrhea (approximately 10 hours). Use this to characterize bowel habit patterns and monitor treatment response.
Use Bristol stool type to qualify for IBS diagnostic criteria (Rome IV): IBS-C requires types 1–2 in more than 25% of stools; IBS-D requires types 6–7 in more than 25% of stools. Track changes over time to assess treatment efficacy.
Gastroenterologists
Apply Bristol Stool Scale to classify IBS subtypes per Rome IV: IBS-C (types 1–2 predominant), IBS-D (types 6–7 predominant), IBS-M (mixed), and IBS-U (unclassified). The BSS is embedded in the official Rome IV diagnostic criteria.
Gastroenterologists
Track Bristol stool type change in response to fiber supplementation, osmotic laxatives (PEG 3350), stimulant laxatives, or prescription agents (lubiprostone, linaclotide). Target shift from types 1–2 toward types 3–4.
IBD nurses
Monitor stool consistency in Crohn's disease and ulcerative colitis patients to track disease activity, treatment response, and distinguish IBD flare from IBS-like functional symptoms during remission.
Dietitians
Assess changes in stool form following dietary modifications — increased fiber, FODMAP diet, probiotic supplementation, or hydration changes. Bristol type provides an objective patient-reported outcome measure.
Researchers
Use as a validated patient-reported outcome (PRO) endpoint in clinical trials for constipation, diarrhea, IBS, and IBD treatments. The FDA PRO Guidance (2009) endorses the Bristol Stool Scale for GI clinical trials.
The Bristol Stool Form Scale is the internationally accepted standard for stool form documentation because it directly correlates with whole gut transit time: Type 1 ≈ 100 hours, Type 4 ≈ 40 hours, Type 7 ≈ 10 hours (Heaton and Lewis, 1997). It is more practical than radiopaque marker transit studies for routine clinical use.
IBS Rome IV subtype classification explicitly uses Bristol types: IBS-C requires types 1–2 in more than 25% of stools (with types 6–7 in less than 25%). IBS-D requires types 6–7 in more than 25% (with types 1–2 in less than 25%). Correct BSS documentation is essential for accurate IBS subtype classification.
Inter-observer reliability of the BSS improves significantly when patients use visual illustrated aids rather than verbal descriptions alone. Digital or laminated BSS cards improve accuracy. When providing the scale verbally without visuals, reliability decreases.
The dietary management goal for both constipation and diarrhea is producing types 3–4 consistently. For constipation: increase fiber (target 25–38 g/day) and fluid intake. For diarrhea: reduce insoluble fiber, increase soluble fiber (psyllium, oat bran). Adequate hydration is essential — 8–10 cups/day minimum.
Persistent loose stools (types 6–7) with red flag symptoms warrant urgent evaluation to exclude organic pathology: rectal bleeding, unintentional weight loss (>5 kg in 6 months), nocturnal symptoms, family history of colorectal cancer (CRC) or IBD, age above 50 with new onset, or iron deficiency anemia.
Loperamide (Imodium) reduces stool frequency and shifts Bristol type from 6–7 toward 3–4 in IBS-D. It is effective for diarrhea symptom control but does not address abdominal pain. For IBS-D with pain, combination therapy (low-dose antidepressant or rifaximin) may be needed.
Polyethylene glycol 3350 (MiraLax, Movicol) is first-line osmotic laxative for functional constipation. It consistently shifts Bristol type from 1–2 toward 3–4 within 1–3 days. Evidence: Ford et al. (Cochrane 2011) — PEG superior to lactulose for stool consistency and frequency.
When patients have persistent type 6–7 stools, fecal calprotectin (normal: below 50 mcg/g) is a cost-effective first-line test to distinguish IBS (normal calprotectin) from IBD (elevated calprotectin, typically above 200 mcg/g). A normal calprotectin has high negative predictive value for IBD.
Children, especially infants and toddlers, have different normal stool patterns. Breastfed infants commonly produce very soft (type 5–6) stools. Standard adult BSS norms do not apply to pediatric patients. Use pediatric-specific reference ranges and the Amsterdam stool scale for young children.
Bristol Stool Form Scale published by Heaton and Lewis (Scand J Gastroenterol 1997). Validated correlation with whole gut transit time: Type 1 = 100h, Type 4 = 40h, Type 7 = 10h. Intra-observer reliability kappa 0.71. IBS Rome IV criteria (Lacy et al., Gastroenterology 2016) reference Bristol types 1–2 for IBS-C and 6–7 for IBS-D. BSS in clinical trials: FDA PRO Guidance (2009) endorses BSS for patient-reported outcomes. Global prevalence of IBS: Sperber et al. (Gastroenterology 2021) — 4.1% using Rome IV criteria.
Lower stool types suggest harder stool and slower transit; higher types indicate looser stool and faster transit.
Use this tool for bowel symptom tracking in constipation, IBS, diarrhea evaluation, and treatment follow-up conversations.
The Bristol scale describes form, not etiology. Diagnosis still requires broader history, alarm-feature screening, and targeted testing when needed.
For related assessments, see Rockall Score, AIMS65 and Water Intake.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Calculate the Rockall score to predict rebleeding and mortality in upper GI hemorrhage. Pre-endoscopy score ≤2: low risk for rebleeding. Post-endoscopy score 0: <5% rebleeding risk.
OpenGastroenterologyEstimate in-hospital mortality risk in upper GI bleeding using the 5-item AIMS65 score.
OpenNutritionCalculate recommended daily water intake based on body weight and activity level, with hydration targets in liters and cups.
OpenNutritionCalculate recommended daily protein intake based on body weight, activity level, and fitness goals.
Open